Selective D1-like dopamine receptor partial agonist (EC50 = 57 nM). Vasodilator in vivo and does not readily cross the blood-brain barrier. Also α2-adrenoceptor antagonist in vitro (Ki = 15 - 25 nM).
Sold for research purposes under agreement from GlaxoSmithKline
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 342.22. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||29.22 mL||146.1 mL||292.21 mL|
|0.5 mM||5.84 mL||29.22 mL||58.44 mL|
|1 mM||2.92 mL||14.61 mL||29.22 mL|
|5 mM||0.58 mL||2.92 mL||5.84 mL|
References are publications that support the biological activity of the product.
Hahn et al (1982) Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. J.Pharmacol.Exp.Ther. 223 305 PMID: 6127401
Nichols et al (1990) The pharmacology of fenoldopam. Am.J.Hypertens. 3 116S PMID: 1974439
Sibley et al (1982) Interactions of novel dopaminergic ligands with D-1 and D-2 dopamine receptors. Life Sci. 31 637 PMID: 6127585
If you know of a relevant reference for Fenoldopam hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Fenoldopam hydrochloride, Fenoldopam hydrochloride supplier, Selective, D1-like, partial, agonists, Dopamine, Receptors, D5, dopaminergic, SKF82526, GlaxoSmithKline, GSK, SKF, 82526, D1, and, 1659, Tocris Bioscience
1 Citation for Fenoldopam hydrochloride
Citations are publications that use Tocris products. Selected citations for Fenoldopam hydrochloride include:
Chen et al (2013) Gastrin and D1 dopamine receptor interact to induce natriuresis and diuresis. Hypertension 62 927 PMID: 24019399
Do you know of a great paper that uses Fenoldopam hydrochloride from Tocris? Please let us know.
Reviews for Fenoldopam hydrochloride
There are currently no reviews for this product. Be the first to review Fenoldopam hydrochloride and earn rewards!
Have you used Fenoldopam hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.